Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

131.84 USD -2.46 (-1.83%)
Official Closing Price Updated: 5:09 PM EDT, Oct 23, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 528,900
Open 134.75
Bid (Size) 128.00 (1)
Ask (Size) 132.00 (10)
Prev. Close 134.30
Today's Range 130.72 - 134.75
52wk Range 83.06 - 167.33
Shares Outstanding 100,522,411
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2020 on Thursday,... 
From Business Wire News Releases
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ILLUMINATE-B Phase 3 pediatric study of... 
From Business Wire News Releases

Performance

YTD
+14.03%
+14.03%
1 Month
-1.12%
-1.12%
3 Month
-16.30%
-16.30%
6 Month
-7.61%
-7.61%
1 Year
+47.72%
+47.72%

More News

Read More
Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
From Business Wire News Releases
Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference
From GlobeNewswire News Releases
Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six
From Business Wire News Releases
Alnylam to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines Conference
From Business Wire News Releases
Alnylam Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ALNY
Tags Stocks
From Market News Video
12 Healthcare Stocks Moving In Thursday's After-Market Session
Tags Health Care ECOR ALNY
From Benzinga
RWDC's Underlying Holdings Could Mean 10% Gain Potential
Tags ETFs
From ETF Channel
9 Biotech Stocks With Material Catalysts In Q4
Tags ZEAL Biotech CRSP
From Benzinga
The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference
Tags Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.